Trial Profile

A Phase 1 Open-label Single Ascending Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of JNJ-77474462 (Bermekimab) in Healthy Chinese Participants Following Subcutaneous Administration

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 29 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bermekimab (Primary)
Indications Atopic dermatitis; Hidradenitis suppurativa; Systemic scleroderma
Focus Pharmacokinetics
Sponsors Janssen Research & Development

20 Dec 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
15 Mar 2022 Planned End Date changed from 24 Oct 2022 to 20 Nov 2023.
15 Mar 2022 Planned primary completion date changed from 24 Oct 2022 to 20 Nov 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com